Leyden Laboratories B.V., an Amsterdam, The Netherlands-based company developing products that protect from known and new respiratory viruses, closed a $140M Series B financing, bringing its total capital raised to approximately $200M in 2021.
Series A investors Casdin Capital and GV (formerly Google Ventures) led the round that included incoming investors SoftBank Vision Fund 2, Invus, and Bluebird Ventures, and existing Series A investors F-Prime Capital and Byers Capital/Brook Byers. The Board will expand to include Eli Casdin of Casdin Capital as a new member. Vali Barsan of Softbank Investment Advisers, Jeff Bird of Bluebird Ventures, and Suzanne Jung Angell of Casdin Capital join the Board as observers.
The proceeds from the financing will support the development of Leyden Labs’ platform, product portfolio, and team.
Led by Koenraad Wiedhaup, founder and CEO, Leyden Labs has developed a platform that targets commonalities of viral families to protect people from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families.
Its platform has been built on two innovative concepts: broad protection against known viruses, new variants and newly emerging viruses, and protection at the gate, in the mucosa (e.g. in the nose and throat). The company has a pipeline of mucosal protection products, including PanFlu which uses CR9114, the only human monoclonal influenza antibody that protects against influenza A and B, in-licensed from Janssen Pharmaceuticals. The platform will also support development of novel broad-protection nasal sprays for coronavirus family and other respiratory diseases.
The team also includes Jaap Goudsmit (CSO), Ronald Brus (CBO), Dinko Valerio (Chair of Supervisory Board), and Suha Jhaveri, CCO.